Martina Rekatsina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martina Rekatsina has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Giustino Varrassi
Research Department, Fondazione Paolo Procacci, 00193 Roma, Italy
18 shared publications - Antonella Paladini
Department of MESVA, University of L’Aquila, 67100 L’Aquila, Italy
7 shared publications - Matteo Luigi Giuseppe Leoni
VIBRA Group, Fondazione Paolo Procacci, 00193 Rome, Italy
6 shared publications - Joseph V. Pergolizzi
NEMA Research, Inc, Naples, USA
4 shared publications - Chryssoula Staikou
First Department of Anesthesiology, “Aretaieio” University Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece
3 shared publications Giustino Varrassi
Fondazione Paolo Procacci, Rome, Italy
3 shared publications
Latest Publications
- Open Access
- 26 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4108
Intrathecal Nalbuphine Versus Other Opioids as Adjuvant to 0.5% Hyperbaric Bupivacaine in Caesarean Section: A Systematic Review and Meta-Analysis
Background/Objectives: Subarachnoid anaesthesia is widely preferred for caesarean delivery due to its rapid onset, reliability, and safety. The addition of adjuvants to intrathecal hyperbaric bupivacaine has been shown to enhance the quality of anaesthesia and prolong postoperative analgesia. Opioids are among the most frequently used intrathecal adjuvants; however, their administration is associated with adverse effects. Nalbuphine, a mixed opioid agonist–antagonist, may be a promising agent for obstetric use due to its favourable pharmacodynamic properties. This study aimed to systematically review and, where feasible, meta-analyse the evidence comparing nalbuphine with other intrathecal opioid adjuvants to hyperbaric bupivacaine 0.5% for caesarean section, with a primary focus on efficacy and safety. Methods: A systematic review and meta-analysis of controlled trials was conducted. Web of Science Core Collection, MEDLINE (PubMed), Scopus, the Library of Congress, and LISTA (EBSCO) were systematically searched to identify eligible studies. Pooled mean difference (MD) and risk ratio (RR) were calculated using random-effects model. Results: Ten studies encompassing 1095 parturients were included. Compared with fentanyl, intrathecal nalbuphine was associated with a modest prolongation of effective analgesia. However, this finding was accompanied by substantial heterogeneity and very low certainty of evidence. In contrast, morphine provided a longer duration of analgesia than nalbuphine. Overall, nalbuphine and fentanyl demonstrated comparable block characteristics, with only minimal and clinically insignificant differences in onset and duration. Importantly, nalbuphine was associated with fewer adverse effects, particularly shivering and PONV. Conclusions: Subarachnoid nalbuphine may serve as a potential alternative adjuvant to 0.5% hyperbaric bupivacaine in caesarean section anaesthesia. It may provide an analgesic efficacy comparable to fentanyl and, although less potent than morphine, it may demonstrate a more favourable safety profile.
- 26 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4108
Open AccessIntrathecal Nalbuphine Versus Other Opioids as Adjuvant to 0.5% Hyperbaric Bupivacaine in Caesarean Section: A Systematic Review and Meta-Analysis
Background/Objectives: Subarachnoid anaesthesia is widely preferred for caesarean delivery due to its rapid onset, reliability, and safety. The addition of adjuvants to intrathecal hyperbaric bupivacaine has been shown to enhance the quality of anaesthesia and prolong postoperative analgesia. Opioids are among the most frequently used intrathecal adjuvants; however, their administration is associated with adverse effects. Nalbuphine, a mixed opioid agonist–antagonist, may be a promising agent for obstetric use due to its favourable pharmacodynamic properties. This study aimed to systematically review and, where feasible, meta-analyse the evidence comparing nalbuphine with other intrathecal opioid adjuvants to hyperbaric bupivacaine 0.5% for caesarean section, with a primary focus on efficacy and safety. Methods: A systematic review and meta-analysis of controlled trials was conducted. Web of Science Core Collection, MEDLINE (PubMed), Scopus, the Library of Congress, and LISTA (EBSCO) were systematically searched to identify eligible studies. Pooled mean difference (MD) and risk ratio (RR) were calculated using random-effects model. Results: Ten studies encompassing 1095 parturients were included. Compared with fentanyl, intrathecal nalbuphine was associated with a modest prolongation of effective analgesia. However, this finding was accompanied by substantial heterogeneity and very low certainty of evidence. In contrast, morphine provided a longer duration of analgesia than nalbuphine. Overall, nalbuphine and fentanyl demonstrated comparable block characteristics, with only minimal and clinically insignificant differences in onset and duration. Importantly, nalbuphine was associated with fewer adverse effects, particularly shivering and PONV. Conclusions: Subarachnoid nalbuphine may serve as a potential alternative adjuvant to 0.5% hyperbaric bupivacaine in caesarean section anaesthesia. It may provide an analgesic efficacy comparable to fentanyl and, although less potent than morphine, it may demonstrate a more favourable safety profile.
- Open Access
- 22 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3647
Long-Term Outcomes of Sacral Neuromodulation for Refractory Interstitial Cystitis/Bladder Pain Syndrome: A Retrospective Cohort Study
Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition characterized by persistent bladder-related pain and urinary symptoms, often refractory to conventional treatments. Sacral neuromodulation (SNM) has emerged as a promising therapeutic option for managing refractory IC/BPS. Methods: This retrospective study included 24 patients with IC/BPS treated with SNM between 2017 and 2022. Baseline and follow-up data were collected on pain, opioid use, urinary symptoms, and quality of life. Patients underwent a trial of tonic stimulation before permanent implantation. Continuous variables were reported as median (IQR) and categorical data as counts and percentages. Pre- and post-SNM differences were analyzed using the Wilcoxon rank-sum test. Kaplan–Meier analysis evaluated lead survival, and a Sankey diagram illustrated employment status transitions. Results: Patients had a median age of 54.5 years (IQR: 47–61), with 92% female. Subtypes included Type 1 IC/BPS (8.3%), Type 2 (45.8%), Type 3 (37.6%), and unknown type (8.3%). Median pain duration was 4.5 years (IQR: 3–7.3). SNM resulted in significant improvements in pain (NRS: baseline 8 [IQR: 8–9], last follow-up 3 [IQR: 2–4], p < 0.0001), opioid use (MME: baseline 20 [IQR: 10–40], last follow-up 0 [IQR: 0–10], p < 0.0001), urinary function (24-h voids: baseline 19 [IQR: 14.5–25.8], last follow-up 8 [IQR: 6–12], p < 0.0001), and quality of life (QOL) (EQ-5D-5L: baseline 0.50 [IQR: 0.36–0.56], last follow-up 0.83 [IQR: 0.76–0.89], p < 0.0001). Employment rates increased from 43.5% to 50%, and unemployment decreased from 8.7% to 4.2%. The median follow-up was 35 months (IQR: 28–53). Conclusions: SNM significantly improved pain, urinary symptoms, quality of life, and employment outcomes in patients with refractory IC/BPS. These findings highlight its efficacy as a minimally invasive and reversible option for managing this challenging condition.
- 22 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3647
Open AccessLong-Term Outcomes of Sacral Neuromodulation for Refractory Interstitial Cystitis/Bladder Pain Syndrome: A Retrospective Cohort Study
Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition characterized by persistent bladder-related pain and urinary symptoms, often refractory to conventional treatments. Sacral neuromodulation (SNM) has emerged as a promising therapeutic option for managing refractory IC/BPS. Methods: This retrospective study included 24 patients with IC/BPS treated with SNM between 2017 and 2022. Baseline and follow-up data were collected on pain, opioid use, urinary symptoms, and quality of life. Patients underwent a trial of tonic stimulation before permanent implantation. Continuous variables were reported as median (IQR) and categorical data as counts and percentages. Pre- and post-SNM differences were analyzed using the Wilcoxon rank-sum test. Kaplan–Meier analysis evaluated lead survival, and a Sankey diagram illustrated employment status transitions. Results: Patients had a median age of 54.5 years (IQR: 47–61), with 92% female. Subtypes included Type 1 IC/BPS (8.3%), Type 2 (45.8%), Type 3 (37.6%), and unknown type (8.3%). Median pain duration was 4.5 years (IQR: 3–7.3). SNM resulted in significant improvements in pain (NRS: baseline 8 [IQR: 8–9], last follow-up 3 [IQR: 2–4], p < 0.0001), opioid use (MME: baseline 20 [IQR: 10–40], last follow-up 0 [IQR: 0–10], p < 0.0001), urinary function (24-h voids: baseline 19 [IQR: 14.5–25.8], last follow-up 8 [IQR: 6–12], p < 0.0001), and quality of life (QOL) (EQ-5D-5L: baseline 0.50 [IQR: 0.36–0.56], last follow-up 0.83 [IQR: 0.76–0.89], p < 0.0001). Employment rates increased from 43.5% to 50%, and unemployment decreased from 8.7% to 4.2%. The median follow-up was 35 months (IQR: 28–53). Conclusions: SNM significantly improved pain, urinary symptoms, quality of life, and employment outcomes in patients with refractory IC/BPS. These findings highlight its efficacy as a minimally invasive and reversible option for managing this challenging condition.
- Open Access
- 2 April 2025
- Published by Springer Nature in Pain and Therapy
- Vol. 14 (3) , 841-863
The Importance of Image Guidance in Common Spine Interventional Procedures for Pain Management: A Comprehensive Narrative Review
Introduction Image-guided spinal injections are commonly performed by pain physicians and supported by literature. A recent survey showed that half of the Canadian providers still perform landmark-guided injections. This comprehensive review aims to describe the evidence supporting imaging modalities (fluoroscopy, computed tomography (CT) and ultrasound) in improving the accuracy and safety in several commonly performed spine injections. Relevant anatomy and pitfalls of landmark-guided injections are also discussed. Methods An extensive literature search was conducted in PubMed, Medline and Embase databases, complemented by a manual search. Search terms included all spine interventions and imaging modalities. Results Literature shows that incorrect needle placement without imaging guidance can reach 50% in caudal, 30.4% in lumbar interlaminar and 53% in cervical interlaminar epidural steroid injections. Lumbar and cervical transforaminal steroid injections require imaging to identify intravascular or intradiscal needle placement; misplacement rates can be as high as 20% at cervical, 8% at thoracic, 6–15% at lumbar and 16.5–21% at sacral levels. Imaging techniques for sacroiliac joint steroid injections are superior to non-imaging techniques, while medial branch blocks and facet joint injections require image guidance. Conclusion Image guidance is a mandatory requirement when performing spinal procedures for pain management. Fluoroscopy enhances the safety and accuracy of spinal injections, with stored images benefiting patient records. Ultrasound also has an increasingly important role either alone or with fluoroscopy. CT is also effective but with limited accessibility.
- 2 April 2025
- Published by Springer Nature in Pain and Therapy
- Vol. 14 (3) , 841-863
Open AccessThe Importance of Image Guidance in Common Spine Interventional Procedures for Pain Management: A Comprehensive Narrative Review
Introduction Image-guided spinal injections are commonly performed by pain physicians and supported by literature. A recent survey showed that half of the Canadian providers still perform landmark-guided injections. This comprehensive review aims to describe the evidence supporting imaging modalities (fluoroscopy, computed tomography (CT) and ultrasound) in improving the accuracy and safety in several commonly performed spine injections. Relevant anatomy and pitfalls of landmark-guided injections are also discussed. Methods An extensive literature search was conducted in PubMed, Medline and Embase databases, complemented by a manual search. Search terms included all spine interventions and imaging modalities. Results Literature shows that incorrect needle placement without imaging guidance can reach 50% in caudal, 30.4% in lumbar interlaminar and 53% in cervical interlaminar epidural steroid injections. Lumbar and cervical transforaminal steroid injections require imaging to identify intravascular or intradiscal needle placement; misplacement rates can be as high as 20% at cervical, 8% at thoracic, 6–15% at lumbar and 16.5–21% at sacral levels. Imaging techniques for sacroiliac joint steroid injections are superior to non-imaging techniques, while medial branch blocks and facet joint injections require image guidance. Conclusion Image guidance is a mandatory requirement when performing spinal procedures for pain management. Fluoroscopy enhances the safety and accuracy of spinal injections, with stored images benefiting patient records. Ultrasound also has an increasingly important role either alone or with fluoroscopy. CT is also effective but with limited accessibility.
- Open Access
- 15 March 2025
- Published by Springer Nature in Pain and Therapy
- Vol. 14 (3) , 775-789
The Role of Biomarkers in Acute Pain: A Narrative Review
Acute pain, a critical aspect of patient care, presents a challenge due to its subjective nature and complex biological underpinnings. Biomarkers for acute pain promise a paradigm shift in how pain is perceived, diagnosed, and managed. The study of genetic, inflammatory, and neurotransmission markers associated with pain experience may hold the key for the development of personalized and effective pain management strategies. This narrative review explores the neurobiological pathways of acute pain, encompassing inflammatory responses and neurotransmission mechanisms. It synthesizes current research on the identification and clinical application of biomarkers, emphasizing their potential to enhance diagnostic precision, treatment effectiveness, and risk prediction. We underscore the promising role of acute pain biomarkers in identifying patients at risk for developing acute and potentially chronic pain, predicting patients’ response to pharmacological interventions, and aiding in the development of novel therapeutic and pain preventive strategies. The evolving landscape of biomarker research not only deepens our understanding of pain mechanisms but also lays the foundation for more tailored and patient-specific healthcare interventions.
- 15 March 2025
- Published by Springer Nature in Pain and Therapy
- Vol. 14 (3) , 775-789
Open AccessThe Role of Biomarkers in Acute Pain: A Narrative Review
Acute pain, a critical aspect of patient care, presents a challenge due to its subjective nature and complex biological underpinnings. Biomarkers for acute pain promise a paradigm shift in how pain is perceived, diagnosed, and managed. The study of genetic, inflammatory, and neurotransmission markers associated with pain experience may hold the key for the development of personalized and effective pain management strategies. This narrative review explores the neurobiological pathways of acute pain, encompassing inflammatory responses and neurotransmission mechanisms. It synthesizes current research on the identification and clinical application of biomarkers, emphasizing their potential to enhance diagnostic precision, treatment effectiveness, and risk prediction. We underscore the promising role of acute pain biomarkers in identifying patients at risk for developing acute and potentially chronic pain, predicting patients’ response to pharmacological interventions, and aiding in the development of novel therapeutic and pain preventive strategies. The evolving landscape of biomarker research not only deepens our understanding of pain mechanisms but also lays the foundation for more tailored and patient-specific healthcare interventions.
- Open Access
- 7 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1792
Correction: Staikou et al. Efficacy and Safety of Pericapsular Nerve Group Block (PENG) in Hip Surgery Under General Anaesthesia: A Systematic Literature Review and Meta-Analysis. J. Clin. Med. 2025, 14, 468
- 7 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1792
Open AccessCorrection: Staikou et al. Efficacy and Safety of Pericapsular Nerve Group Block (PENG) in Hip Surgery Under General Anaesthesia: A Systematic Literature Review and Meta-Analysis. J. Clin. Med. 2025, 14, 468
- Open Access
- 13 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (2) , 468
Efficacy and Safety of Pericapsular Nerve Group Block (PENG) in Hip Surgery Under General Anaesthesia: A Systematic Literature Review and Meta-Analysis
Background: The pericapsular nerve group (PENG) block is a novel ultrasound-guided regional technique that may provide analgesia to patients undergoing hip surgery. It has been extensively studied in recent years, but the evidence of superiority over other regional anaesthetic techniques is inconclusive. This review aimed to compare outcomes of the PENG block in patients undergoing hip surgery with standard techniques under general anaesthesia. Methods: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed throughout the preparation of this review. Randomised trials from electronic databases were included. We investigated postoperative pain scores, required analgesia, and adverse events associated with the block. Results: Ten studies satisfied the criteria to be included in the meta-analysis. Data from 646 patients were analysed, in which 321 patients received PENG block and 325 were included in the comparative groups. Pain scores at rest, at 24 h (p = 0.04) and 48 h (p = 0.02) were lower in patients who had received the PENG block. This group also required a smaller amount of opioids at 24 h after the procedure, but this difference was not statistically significant (p = 0.53); while a similar non-significant reduction in opioid consumption was also observed at 48 h. Although PENG seems to delay the time to the first analgesic request, we failed to prove a statistically significant difference (p = 0.83). Patient satisfaction also seems to be better in the PENG group, but not in a statistically significant way. No important side effects related to the block were described. Conclusions: PENG block for major hip surgery offers better postoperative analgesia, with possibly less opioid consumption. It seems to prolong the time to the first analgesic but does not significantly affect common side effects of anaesthesia/analgesia such as PONV or duration of hospital stay.
- 13 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (2) , 468
Open AccessEfficacy and Safety of Pericapsular Nerve Group Block (PENG) in Hip Surgery Under General Anaesthesia: A Systematic Literature Review and Meta-Analysis
Background: The pericapsular nerve group (PENG) block is a novel ultrasound-guided regional technique that may provide analgesia to patients undergoing hip surgery. It has been extensively studied in recent years, but the evidence of superiority over other regional anaesthetic techniques is inconclusive. This review aimed to compare outcomes of the PENG block in patients undergoing hip surgery with standard techniques under general anaesthesia. Methods: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed throughout the preparation of this review. Randomised trials from electronic databases were included. We investigated postoperative pain scores, required analgesia, and adverse events associated with the block. Results: Ten studies satisfied the criteria to be included in the meta-analysis. Data from 646 patients were analysed, in which 321 patients received PENG block and 325 were included in the comparative groups. Pain scores at rest, at 24 h (p = 0.04) and 48 h (p = 0.02) were lower in patients who had received the PENG block. This group also required a smaller amount of opioids at 24 h after the procedure, but this difference was not statistically significant (p = 0.53); while a similar non-significant reduction in opioid consumption was also observed at 48 h. Although PENG seems to delay the time to the first analgesic request, we failed to prove a statistically significant difference (p = 0.83). Patient satisfaction also seems to be better in the PENG group, but not in a statistically significant way. No important side effects related to the block were described. Conclusions: PENG block for major hip surgery offers better postoperative analgesia, with possibly less opioid consumption. It seems to prolong the time to the first analgesic but does not significantly affect common side effects of anaesthesia/analgesia such as PONV or duration of hospital stay.
- Open Access
- 13 January 2025
- Published by MDPI AG in Clinics and Practice
- Vol. 15 (1) , 16
Role of Cannabis in the Management of Chronic Non-Cancer Pain: A Narrative Review
Chronic non-cancer pain, defined by the Center for Disease Control and Prevention (CDC) as lasting beyond three months, significantly affects individuals’ quality of life and is often linked to various medical conditions or injuries. Its management is complex. Cannabis, containing the key compounds Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), has garnered interest for its potential in pain management, though it remains controversial due to its psychoactive effects and illegal status in many countries. THC provides pain relief by blocking nociceptive stimuli but has psychoactive effects and may potentially induce dependency. CBD has calming and antipsychotic properties. The inhalation of cannabis offers quick relief but poses respiratory risks, while its oral administrations are safer but act more slowly. Short-term cannabis use can impair cognition and motor skills, while long-term use may lead to dependency and cognitive decline, especially if used from an early age. Adverse effects vary by gender and prior use, with addiction mainly linked to THC and influenced by genetics. Despite these risks, patients often report more benefits, such as improved quality of life and reduced opioid use, although the evidence remains inconclusive. The legal landscape for medical cannabis varies globally, with some positive public health outcomes like reduced opioid-related issues in areas where it is legalized. Cannabis shows promise in managing chronic pain, but its psychoactive effects and dependency risks necessitate cautious use. Future research should prioritize long-term clinical trials to establish optimal dosing, efficacy, and safety, aiding in the development of informed guidelines for safe cannabis use in chronic pain management. This review examines the use of cannabis in managing chronic non-cancer pain, focusing on its benefits, drawbacks, mechanisms, delivery methods, and impact on quality of life.
- 13 January 2025
- Published by MDPI AG in Clinics and Practice
- Vol. 15 (1) , 16
Open AccessRole of Cannabis in the Management of Chronic Non-Cancer Pain: A Narrative Review
Chronic non-cancer pain, defined by the Center for Disease Control and Prevention (CDC) as lasting beyond three months, significantly affects individuals’ quality of life and is often linked to various medical conditions or injuries. Its management is complex. Cannabis, containing the key compounds Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), has garnered interest for its potential in pain management, though it remains controversial due to its psychoactive effects and illegal status in many countries. THC provides pain relief by blocking nociceptive stimuli but has psychoactive effects and may potentially induce dependency. CBD has calming and antipsychotic properties. The inhalation of cannabis offers quick relief but poses respiratory risks, while its oral administrations are safer but act more slowly. Short-term cannabis use can impair cognition and motor skills, while long-term use may lead to dependency and cognitive decline, especially if used from an early age. Adverse effects vary by gender and prior use, with addiction mainly linked to THC and influenced by genetics. Despite these risks, patients often report more benefits, such as improved quality of life and reduced opioid use, although the evidence remains inconclusive. The legal landscape for medical cannabis varies globally, with some positive public health outcomes like reduced opioid-related issues in areas where it is legalized. Cannabis shows promise in managing chronic pain, but its psychoactive effects and dependency risks necessitate cautious use. Future research should prioritize long-term clinical trials to establish optimal dosing, efficacy, and safety, aiding in the development of informed guidelines for safe cannabis use in chronic pain management. This review examines the use of cannabis in managing chronic non-cancer pain, focusing on its benefits, drawbacks, mechanisms, delivery methods, and impact on quality of life.
- Open Access
- 7 January 2025
- Published by MDPI AG in Preprints.org
Trends in Labor Analgesia: Analysis of Patients’ Web Searches Across Europe Using a Machine Learning Model
Epidural analgesia is widely regarded as the gold standard for pain relief during labor. Despite its effectiveness, significant disparities in adoption persist due to cultural, medical, and informational factors. This study aimed to analyze online search behaviors related to epidural analgesia in the six most populous European countries, evaluate temporal trends, and assess the predictive power of machine learning models for search volumes.MethodsWeekly search data from 2020 to 2024 were obtained from Google Trends for France, Germany, Italy, Spain, Turkey, and the United Kingdom (UK). Data were analyzed using linear regression, time-series decomposition, and Mann-Kendall tests to identify monotonic trends. An Auto Regressive Integrated Moving Average (ARIMA) model was developed to forecast search volumes for 2025. Machine learning models such as Random Forest (RF) and Gradient Boosting Machine (GBM), were employed to evaluate the influence of variables such as country and temporal factors on search patterns. Model performance was assessed using specific metric (R², RMSE, MAE, and MBE) and statistical comparisons were made between the models.ResultsFrance and Turkey exhibited significant downward trends in search interest, while Germany showed a slight upward trend, and Italy, Spain, and the UK demonstrated stable patterns. ARIMA forecast indicated stable search volumes for most countries, with the UK reaching the highest activity. RF outperformed GBM, achieving R² values of 0.92 (testing) and 0.93 (training), with "Country" identified as the most influential predictor. Associated queries highlighted common public concerns, including epidural timing, risks, and side effects.ConclusionsThese findings reveal the value of understanding public interest in epidural analgesia to address concerns effectively. Healthcare providers should guide patients toward reliable online information. Future initiatives should include educational tools, national health programs, and interdisciplinary collaboration to enhance informed decision-making and optimize maternal care outcomes.
- 7 January 2025
- Published by MDPI AG in Preprints.org
Open AccessTrends in Labor Analgesia: Analysis of Patients’ Web Searches Across Europe Using a Machine Learning Model
Epidural analgesia is widely regarded as the gold standard for pain relief during labor. Despite its effectiveness, significant disparities in adoption persist due to cultural, medical, and informational factors. This study aimed to analyze online search behaviors related to epidural analgesia in the six most populous European countries, evaluate temporal trends, and assess the predictive power of machine learning models for search volumes.MethodsWeekly search data from 2020 to 2024 were obtained from Google Trends for France, Germany, Italy, Spain, Turkey, and the United Kingdom (UK). Data were analyzed using linear regression, time-series decomposition, and Mann-Kendall tests to identify monotonic trends. An Auto Regressive Integrated Moving Average (ARIMA) model was developed to forecast search volumes for 2025. Machine learning models such as Random Forest (RF) and Gradient Boosting Machine (GBM), were employed to evaluate the influence of variables such as country and temporal factors on search patterns. Model performance was assessed using specific metric (R², RMSE, MAE, and MBE) and statistical comparisons were made between the models.ResultsFrance and Turkey exhibited significant downward trends in search interest, while Germany showed a slight upward trend, and Italy, Spain, and the UK demonstrated stable patterns. ARIMA forecast indicated stable search volumes for most countries, with the UK reaching the highest activity. RF outperformed GBM, achieving R² values of 0.92 (testing) and 0.93 (training), with "Country" identified as the most influential predictor. Associated queries highlighted common public concerns, including epidural timing, risks, and side effects.ConclusionsThese findings reveal the value of understanding public interest in epidural analgesia to address concerns effectively. Healthcare providers should guide patients toward reliable online information. Future initiatives should include educational tools, national health programs, and interdisciplinary collaboration to enhance informed decision-making and optimize maternal care outcomes.
- Open Access
- 4 December 2024
- Published by Springer Nature in Pain and Therapy
- Vol. 14 (1) , 81-101
A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review
Palmitoylethanolamide (PEA) has been prescribed in neuropathic pain management for over 20 years. This study aims to summarize what has been published on the topic in the last 15 years and determine the appropriateness of the prescribing. It describes the pharmacological aspect of PEA, especially focusing on its pharmacodynamics and pharmacokinetics. Then, it deeply explores why PEA may be useful in the pharmacological management of both neuropathic and mixed pain. Finally, it examines some innovative patent, which aims to address obstacles encountered with conventional PEA formulations, for its pharmacodynamic characteristics. One of them (Equisetum-PEA) seems promising. It partially ameliorates the bioavailability and the targeted distribution. It seems to introduce novel advancements that can potentially enhance the therapeutic effectiveness of PEA in terms of its anti-inflammatory, antioxidant, and analgesic properties. The deep literature analysis aims to examine the potential advantages of PEA, in the context of several pathological conditions that may benefit from this molecule. It focuses on various published data regarding the clinical efficacy of PEA in managing neuropathic and mixed pain. Also, it tries to understand if it can modernize the field of therapy based on PEA, thus offering a better treatment option for individuals with chronic long-term inflammation, oxidative stress, and neuropathic or mixed pain with a neuropathic component. The study examines the possible impact of PEA on personalized medicine strategies and its potential for translation into clinical practice. It analyses the possibilities that PEA has in enhancing patient outcomes in a range of central nervous system and inflammatory conditions. A complete analysis of the therapeutic potentialities of this product was missing. This extensive narrative review makes a valuable contribution to the ongoing comprehension of PEA therapy. It establishes a foundation for further exploration in research and potential uses in clinical settings.
- 4 December 2024
- Published by Springer Nature in Pain and Therapy
- Vol. 14 (1) , 81-101
Open AccessA Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review
Palmitoylethanolamide (PEA) has been prescribed in neuropathic pain management for over 20 years. This study aims to summarize what has been published on the topic in the last 15 years and determine the appropriateness of the prescribing. It describes the pharmacological aspect of PEA, especially focusing on its pharmacodynamics and pharmacokinetics. Then, it deeply explores why PEA may be useful in the pharmacological management of both neuropathic and mixed pain. Finally, it examines some innovative patent, which aims to address obstacles encountered with conventional PEA formulations, for its pharmacodynamic characteristics. One of them (Equisetum-PEA) seems promising. It partially ameliorates the bioavailability and the targeted distribution. It seems to introduce novel advancements that can potentially enhance the therapeutic effectiveness of PEA in terms of its anti-inflammatory, antioxidant, and analgesic properties. The deep literature analysis aims to examine the potential advantages of PEA, in the context of several pathological conditions that may benefit from this molecule. It focuses on various published data regarding the clinical efficacy of PEA in managing neuropathic and mixed pain. Also, it tries to understand if it can modernize the field of therapy based on PEA, thus offering a better treatment option for individuals with chronic long-term inflammation, oxidative stress, and neuropathic or mixed pain with a neuropathic component. The study examines the possible impact of PEA on personalized medicine strategies and its potential for translation into clinical practice. It analyses the possibilities that PEA has in enhancing patient outcomes in a range of central nervous system and inflammatory conditions. A complete analysis of the therapeutic potentialities of this product was missing. This extensive narrative review makes a valuable contribution to the ongoing comprehension of PEA therapy. It establishes a foundation for further exploration in research and potential uses in clinical settings.
- Open Access
- 18 March 2024
- Published by PAGEPress Publications in Advancements in Health Research
- Vol. 1 (1)
Piezo channels in migraine and trigeminal pain syndromes: a systematic review of their role in pain pathways
Piezo channels, a class of mechanosensitive ion channels, have emerged as key players in sensory transduction. Piezo1 and Piezo2 have been implicated in various physiological processes, including touch sensation and nociception. Their association with migraine and their role in pain involving trigeminal nerve have gained significant research attention. Following PRISMA guidelines, we performed a systematic review of the literature, on the role of Piezo1 and Piezo2 channels in migraine and trigeminal pain. From PubMed, Cochrane Library, and Scopus, we deemed 20 studies published between 2014 and 2023 appropriate to be included in this review. Piezo1 emerges as a key player in migraine pathogenesis, contributing to meningeal nociception and pain generation. In trigeminal pain syndromes, Piezo channels, particularly Piezo2, have a role in various pain conditions, from corneal nociception to dental and orofacial pain. Mechanistic insights provide potential therapeutic targets for migraine and other pain conditions involving trigeminal nerve. This systematic review accentuates the emerging significance of Piezo channels in migraine and trigeminal-associated pain, underscoring cross-associations that interconnect Piezo channels, migraine, and trigeminal neurons, as well as suggesting promising avenues for targeted therapeutic interventions and future research directions.
- 18 March 2024
- Published by PAGEPress Publications in Advancements in Health Research
- Vol. 1 (1)
Open AccessPiezo channels in migraine and trigeminal pain syndromes: a systematic review of their role in pain pathways
Piezo channels, a class of mechanosensitive ion channels, have emerged as key players in sensory transduction. Piezo1 and Piezo2 have been implicated in various physiological processes, including touch sensation and nociception. Their association with migraine and their role in pain involving trigeminal nerve have gained significant research attention. Following PRISMA guidelines, we performed a systematic review of the literature, on the role of Piezo1 and Piezo2 channels in migraine and trigeminal pain. From PubMed, Cochrane Library, and Scopus, we deemed 20 studies published between 2014 and 2023 appropriate to be included in this review. Piezo1 emerges as a key player in migraine pathogenesis, contributing to meningeal nociception and pain generation. In trigeminal pain syndromes, Piezo channels, particularly Piezo2, have a role in various pain conditions, from corneal nociception to dental and orofacial pain. Mechanistic insights provide potential therapeutic targets for migraine and other pain conditions involving trigeminal nerve. This systematic review accentuates the emerging significance of Piezo channels in migraine and trigeminal-associated pain, underscoring cross-associations that interconnect Piezo channels, migraine, and trigeminal neurons, as well as suggesting promising avenues for targeted therapeutic interventions and future research directions.